Here are some publications where I am acknowledged as providing medical writing support or that I have authored

Autoimmune diseases

Primary manuscript: Sabet A, et al. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects. Rheumatol Ther 2022; 9:693-704.

Review: Peyrin-Biroulet L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021; 14:17562848211059954.

Review: Taylor PC, et al. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med 2021; 10(3):509.

Primary manuscript: Hercogová J, et al. AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis. Br J Dermatol 2020; 182:316-26.

Primary manuscript: Edwards C, et al. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol 2019; 38:3381-3390.

Poster: Hercogová J, et al. Safety, immunogenicity, and efficacy after a single switch from reference adalimumab to the proposed biosimilar MSB11022: Long-term results from a randomized, double-blind, 52-week, phase III study in moderate-to-severe plaque-type psoriasis patients. Presented at the American Academy of Dermatology Annual Meeting 2019. 

Review: Baumgart DC, et al. Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front Pharmacol 2019; 10:279.

Review: Edwards CJ, et al. Switching to biosimilars: Current perspectives in immune-mediated inflammatory diseases. Expert Opin Biol Ther 2019; 19:1001-14.


KOL interview: Gibbs H, Klok FA. New developments, data, and guideline updates: Direct oral anticoagulants for the treatment of venous thromboembolism associated with cancer - interviews with key opinion leaders. EMJ 2022;10(Suppl 3):2-8.


Primary manuscript: Hock AK, Vigneron A, Carter S, et al. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J 2011; 30:4921-30.

Primary manuscript: Stindt MH, Carter S, et al. MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 2011; 10:3176-88.

Review: Carter S and Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24.

Primary manuscript: Carter S and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 2008; 7:2519-28.

Review: Carter S and Vousden KH. A role for Numb in p53 stabilization. Genome Biol 2008; 9:221.

Primary manuscript: Carter S, et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nature Cell Biol 2007; 9:428-35.

Primary manuscript: Carter S, et al. The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity. J Biol Chem 2004; 279:52835-9.

Review: Hammond DE, Carter S, et al. Met receptor dynamics and signalling. Curr Top Microbiol Immunol 2004; 286:21-44.

Primary manuscript: Hammond DE, Carter S, et al. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003; 14: 1346-54.